mGlu2/3 antagonists and negative allosteric modulators, such as decoglurant, have thus far failed to demonstrate efficacy in patients with MDD with an inadequate response to pharmacotherapy (EudraCT number 2011-002160-24) [107,108]. Here, GRM2 is linked to major depressive disorder.